Clinical trials
Metastatic Cancer clinical trials
Below are recruiting metastatic cancer clinical trials, each written for real people, not researchers. We’re tracking 1,862 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06079983RecruitingPhase 3
JSKN003 vs. doctor's choice for HER2-low breast cancer
This trial compares a new experimental drug, JSKN003, to standard treatments chosen by your doctor for advanced breast cancer that tests as HER2-low (IHC 1+ or 2+ but not amplified). It's for people whose cancer has spread or can't be removed and who have already had one or two lines of chemotherapy.
Guangzhou, GuangdongAges 18 years+ - NCT05404139RecruitingPhase 2
Short hormone therapy and radiation for prostate cancer that has spread a little
This trial tests a shorter course of hormone therapy plus targeted radiation for prostate cancer that has spread to a few spots (oligometastatic). The goal is to see if less hormone therapy can still control the cancer effectively.
Toronto, OntarioAges 18–100 - NCT05168163RecruitingPhase 2
Atezolizumab plus targeted drug for advanced liver cancer
This Phase 2 study tests whether atezolizumab combined with a multi-targeted (“multi-kinase”) inhibitor can treat advanced liver cancer that cannot be cured with surgery or local procedures. It focuses on people whose cancer has already grown despite a first-line treatment using atezolizumab plus bevacizumab.
Scottsdale, ArizonaAges 18 years+ - NCT04927416RecruitingPhase 2
Ga-DOTATATE PET/CT scan in metastatic thyroid cancer
This study tests whether a specific special scan (68-Gallium DOTATATE PET/CT) can help doctors better see where thyroid cancer has spread. It focuses on certain types of thyroid cancer and compares how well the scan images metastases.
Bethesda, MarylandAges 18–98 - NCT04174352RecruitingEarly Phase 1
FES scan to guide tamoxifen for metastatic breast cancer
This early-phase study uses a special PET scan (FES PET/CT) to better match tamoxifen treatment to people with estrogen-receptor–positive breast cancer that has spread. It aims to see whether the scan results can help optimize tamoxifen use and potentially improve outcomes.
Madison, WisconsinAges 19 years+ - NCT07130032RecruitingPhase 2
Immunotherapy combo for advanced lung cancer or melanoma
This trial tests a combination of immunotherapy drugs (anti-PD-1/PD-L1 antibodies) plus bevacizumab and a low-dose chemotherapy called cyclophosphamide for people with advanced lung cancer or melanoma who have already been on immunotherapy and their cancer has progressed.
Saint Petersburg, Sankt-PeterburgAges 18 years+ - NCT07415564Recruiting
Support program for advanced cancer patients and their caregivers
This trial offers coaching and symptom management support for people with advanced breast, GI, or melanoma cancer and their caregivers. The goal is to improve quality of life for both.
Tucson, ArizonaAges 18 years+ - NCT07240610Recruiting
Radiation and immunotherapy for kidney cancer that has spread
This trial tests whether adding a special type of radiation to your current immunotherapy can help shrink kidney cancer tumors that have stopped responding or are stable. The goal is to see if the radiation can boost the immune system's ability to fight cancer elsewhere in the body.
Chūō, YamanashiAges 18 years+ - NCT07191418Recruiting
Study of ERCP with RFA for pancreatic cancer with liver spread
This study tests a combination of endoscopic procedures (ERCP and RFA) to open the blocked bile duct and treat the tumor with heat in people with pancreatic cancer that has spread to the liver. The goal is to see if this approach can help relieve symptoms and improve outcomes while you continue chemotherapy.
UmeåAges 18–85 - NCT07062536RecruitingPhase 2
Comparing Two Chemo Combos for Advanced Bile Duct Cancer
This trial compares two chemotherapy combinations (mFOLFOX and mFOLFIRI) against just one of them (mFOLFOX) for people with advanced bile duct or gallbladder cancer that has progressed after standard first-line treatment. The goal is to see which works better as a second treatment option.
Busan, BusanAges 19–99 - NCT05283044Recruiting
Precision medicine testing for advanced, hard-to-remove cancers
This study helps doctors use more individualized (precision) treatment choices for people with certain advanced cancers. You may be offered study care based on your cancer details, aiming to improve treatment decisions.
BayonneAges 18 years+ - NCT06911008RecruitingPhase 1
Study of a new drug for advanced solid tumors
This study tests an experimental drug called MTI-301 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug can shrink tumors or slow their growth, and to check its safety.
Jacksonville, FloridaAges 18 years+ - NCT05985330Recruiting
Study of FeNO as a marker for immunotherapy response in lung cancer
This trial is testing whether a simple breath test (FeNO) can predict how well immunotherapy works in people with advanced lung cancer who haven't had treatment before. It's for patients whose tumors have high PD-L1 levels and who will receive immunotherapy alone.
DijonAges 18 years+ - NCT05864794Recruiting
Screening brain MRI in advanced lung cancer patients
This trial looks at whether doing an MRI scan of the brain for people with stage IV lung cancer helps in their care. The goal is to find brain issues early (if present) so treatment decisions can be made sooner.
Groningen, Provincie GroningenAges 18 years+ - NCT04613596RecruitingPhase 2/Phase 3
Adagrasib for KRAS G12C lung cancer, alone or with pembrolizumab
This trial studies adagrasib (an anti-cancer drug) either alone or with pembrolizumab (an immunotherapy) in people with advanced lung cancer that has a KRAS G12C mutation. It aims to shrink tumors and improve outcomes, including for people without urgent brain treatment needs.
Goodyear, ArizonaAges 18 years+ - NCT06844383RecruitingPhase 2
Talazoparib with or without enzalutamide for prostate cancer after prior treatment
This study tests a drug called talazoparib, either alone or combined with enzalutamide, in people with prostate cancer that has spread and has a specific genetic change. The goal is to see if this treatment can help control the cancer after previous therapies have stopped working.
Duarte, CaliforniaAges 18 years+ - NCT07407608Recruiting
Radiation therapy for unfavorable prostate cancer
This trial tests a type of focused radiation therapy for men with intermediate or high-risk prostate cancer that hasn't spread. It aims to improve outcomes by targeting the main tumor seen on MRI.
Monza, MBAges 18–90 - NCT07200830RecruitingPhase 3
Testing different schedules of a targeted radiation drug for advanced prostate cancer
This trial tests two different dosing schedules of a drug called Lutetium-177 PSMA RLT, which delivers radiation directly to prostate cancer cells. It is for men with advanced prostate cancer that has stopped responding to hormone therapy and has spread, who have not yet had chemotherapy for this stage of the disease.
Anchorage, AlaskaAges 18 years+ - NCT07459751RecruitingPhase 2/Phase 3
A study of HLX43 alone or with HLX07 vs docetaxel for advanced squamous lung cancer
This trial tests a new drug called HLX43, given alone or with HLX07, against the standard chemo docetaxel for people with a type of advanced lung cancer called squamous non-small cell lung cancer. It's for patients who have already tried and not responded to platinum chemo and immunotherapy.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06500481RecruitingPhase 3
Proton vs standard radiation for cancer spread to brain/spine lining
This trial compares a newer type of radiation (proton therapy) to standard radiation for people whose breast or lung cancer has spread to the lining of the brain and spinal cord. It aims to see if proton therapy can better control the disease while causing fewer side effects.
Phoenix, ArizonaAges 18 years+ - NCT05741164RecruitingPhase 2
Propranolol plus pembrolizumab for hard-to-treat breast cancer
This Phase 2 trial studies whether adding propranolol to pembrolizumab can “re-sensitize” tumors and slow cancer in triple-negative breast cancer that no longer responds to checkpoint immunotherapy. It may help some people whose cancer has grown despite prior pembrolizumab and chemotherapy.
Atlanta, GeorgiaAges 18 years+ - NCT06260033RecruitingPhase 2
Radiation Therapy for Oligoprogressive ER+ Breast Cancer
This trial tests whether a precise radiation treatment (SBRT) can target a few growing spots of estrogen receptor-positive breast cancer that has spread to other parts of the body. It also uses a special PET scan (FES PET/CT) to see how well the cancer responds. The goal is to slow down the cancer and delay the need for stronger treatments.
Duarte, CaliforniaAges 18 years+ - NCT06395519RecruitingPhase 1/Phase 2
Study of ETX-19477 for advanced solid tumors
This trial tests an experimental drug called ETX-19477 for people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective, especially for those with certain genetic changes (BRCA2 mutations).
Phoenix, ArizonaAges 18 years+ - NCT04222413RecruitingPhase 1
Study of metarrestin for advanced solid tumors
This study tests an experimental drug called metarrestin for people with solid tumors that have spread or come back after standard treatment. It may help by targeting a protein involved in cancer cell growth.
Fairway, KansasAges 12–120
Hear when a new Metastatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic cancer?
- Yes. Clin2 currently lists 1,862 recruiting metastatic cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Beyond the search
We also like to point to nonprofits doing real good in this area. We aren’t affiliated with them — we just admire the work.
- Stand Up To CancerPeople facing cancer across many types, through the research that leads to better treatments.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.